TP53 and metastatic malignant neoplasm: For patients with TP53 and APC mutations (62% harbored at least one of these alterations), indirect therapeutic strategies are needed to address the consequences of loss of function in these critical tumor-suppressor mechanisms.15,16 Although we have not yet compared the NCI-MATCH specimens with the patients’ primary tumors, the available data from TCGA and NCI-MATCH suggest there is not substantial evolution in the genetic features from primary to metastatic cancers.